Next Article in Journal
Immunomodulatory Potential of Tinospora cordifolia and CpG ODN (TLR21 Agonist) against the Very Virulent, Infectious Bursal Disease Virus in SPF Chicks
Next Article in Special Issue
Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV
Previous Article in Journal
Production Strategies for Pentamer-Positive Subviral Dense Bodies as a Safe Human Cytomegalovirus Vaccine
Previous Article in Special Issue
Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections

Peptide-Based Vaccination for Antibody Responses Against HIV

Sorbonne University, UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Center of Immunology and Infectious Diseases (CIMI-Paris), 91 Boulevard de l’Hôpital, F-75013 Paris, France
Author to whom correspondence should be addressed.
Vaccines 2019, 7(3), 105;
Received: 16 July 2019 / Revised: 29 August 2019 / Accepted: 30 August 2019 / Published: 2 September 2019
(This article belongs to the Special Issue Advances in Antibody-based HIV-1 Vaccine Development)
HIV-1 is responsible for a global pandemic of 35 million people and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, whereas a therapeutic vaccine might help to mitigate the clinical course of the disease and to contribute to virus eradication strategies. However, despite more than 30 years of research, we do not have a vaccine capable of protecting against HIV-1 infection or impacting on disease progression. This, in part, denotes the challenge of identifying immunogens and vaccine modalities with a reduced risk of failure in late stage development. However, progress has been made in epitope identification for the induction of broadly neutralizing antibodies. Thus, peptide-based vaccination has become one of the challenges of this decade. While some researchers reconstitute envelope protein conformation and stabilization to conserve the epitope targeted by neutralizing antibodies, others have developed strategies based on peptide-carrier vaccines with a similar goal. Here, we will review the major peptide-carrier based approaches in the vaccine field and their application and recent development in the HIV-1 field. View Full-Text
Keywords: peptide-conjugate; HIV-1; neutralizing antibodies; vaccination; adjuvants peptide-conjugate; HIV-1; neutralizing antibodies; vaccination; adjuvants
MDPI and ACS Style

Combadière, B.; Beaujean, M.; Chaudesaigues, C.; Vieillard, V. Peptide-Based Vaccination for Antibody Responses Against HIV. Vaccines 2019, 7, 105.

AMA Style

Combadière B, Beaujean M, Chaudesaigues C, Vieillard V. Peptide-Based Vaccination for Antibody Responses Against HIV. Vaccines. 2019; 7(3):105.

Chicago/Turabian Style

Combadière, Behazine, Manon Beaujean, Chloé Chaudesaigues, and Vincent Vieillard. 2019. "Peptide-Based Vaccination for Antibody Responses Against HIV" Vaccines 7, no. 3: 105.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop